| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition | 45 | 2020 | 576 | 4.910 |
Why?
|
| Cognition Disorders | 31 | 2020 | 390 | 4.690 |
Why?
|
| Dementia | 25 | 2020 | 252 | 4.050 |
Why?
|
| Women's Health | 19 | 2020 | 242 | 2.430 |
Why?
|
| Postmenopause | 28 | 2020 | 461 | 2.260 |
Why?
|
| Neuropsychological Tests | 25 | 2019 | 372 | 1.680 |
Why?
|
| Aged | 95 | 2020 | 10998 | 1.580 |
Why?
|
| Hormone Replacement Therapy | 8 | 2020 | 96 | 1.480 |
Why?
|
| Aging | 13 | 2020 | 1010 | 1.400 |
Why?
|
| Female | 113 | 2020 | 21490 | 1.360 |
Why?
|
| Brain Neoplasms | 11 | 2019 | 649 | 1.330 |
Why?
|
| Aged, 80 and over | 49 | 2020 | 4150 | 1.320 |
Why?
|
| Quality of Life | 20 | 2019 | 1032 | 1.240 |
Why?
|
| Piperidines | 5 | 2015 | 141 | 1.210 |
Why?
|
| Humans | 127 | 2020 | 34474 | 1.150 |
Why?
|
| Indans | 3 | 2015 | 36 | 1.130 |
Why?
|
| Middle Aged | 63 | 2020 | 12703 | 1.040 |
Why?
|
| Estrogens, Conjugated (USP) | 15 | 2020 | 159 | 1.030 |
Why?
|
| Brain | 8 | 2020 | 1031 | 1.020 |
Why?
|
| Memory | 13 | 2019 | 216 | 0.930 |
Why?
|
| Geriatric Assessment | 7 | 2020 | 369 | 0.850 |
Why?
|
| Estrogen Replacement Therapy | 11 | 2020 | 222 | 0.840 |
Why?
|
| Activities of Daily Living | 6 | 2020 | 267 | 0.830 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2015 | 42 | 0.800 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2020 | 1523 | 0.780 |
Why?
|
| Antihypertensive Agents | 3 | 2020 | 378 | 0.770 |
Why?
|
| Hypertension | 5 | 2020 | 1024 | 0.770 |
Why?
|
| Life Style | 8 | 2020 | 418 | 0.750 |
Why?
|
| Medroxyprogesterone Acetate | 11 | 2020 | 115 | 0.730 |
Why?
|
| Affect | 7 | 2018 | 72 | 0.720 |
Why?
|
| Male | 63 | 2020 | 20697 | 0.710 |
Why?
|
| Executive Function | 3 | 2017 | 60 | 0.670 |
Why?
|
| Blood Pressure | 4 | 2020 | 901 | 0.650 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2017 | 53 | 0.610 |
Why?
|
| Cranial Irradiation | 1 | 2019 | 95 | 0.590 |
Why?
|
| Atherosclerosis | 5 | 2018 | 837 | 0.580 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2020 | 1386 | 0.580 |
Why?
|
| Longitudinal Studies | 15 | 2020 | 801 | 0.570 |
Why?
|
| Follow-Up Studies | 21 | 2020 | 2366 | 0.570 |
Why?
|
| Diet | 2 | 2019 | 418 | 0.560 |
Why?
|
| Survivors | 3 | 2018 | 177 | 0.560 |
Why?
|
| Risk Factors | 23 | 2020 | 4136 | 0.550 |
Why?
|
| Behavior Therapy | 3 | 2018 | 107 | 0.530 |
Why?
|
| Alzheimer Disease | 6 | 2020 | 294 | 0.520 |
Why?
|
| Fatigue | 5 | 2019 | 90 | 0.490 |
Why?
|
| Coronary Vessels | 1 | 2017 | 180 | 0.470 |
Why?
|
| United States | 19 | 2020 | 4267 | 0.460 |
Why?
|
| Health Behavior | 3 | 2019 | 246 | 0.450 |
Why?
|
| Calcium | 1 | 2017 | 343 | 0.450 |
Why?
|
| Incidence | 9 | 2020 | 1288 | 0.440 |
Why?
|
| Estrogens | 6 | 2013 | 210 | 0.430 |
Why?
|
| Geriatrics | 1 | 2015 | 88 | 0.430 |
Why?
|
| Acne Vulgaris | 2 | 2006 | 102 | 0.430 |
Why?
|
| Inflammation | 2 | 2017 | 557 | 0.420 |
Why?
|
| Adult | 26 | 2019 | 10015 | 0.420 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 441 | 0.420 |
Why?
|
| Breast Neoplasms | 4 | 2015 | 803 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2019 | 565 | 0.410 |
Why?
|
| Radiotherapy | 4 | 2019 | 90 | 0.410 |
Why?
|
| Proportional Hazards Models | 10 | 2020 | 803 | 0.400 |
Why?
|
| Educational Status | 2 | 2018 | 185 | 0.400 |
Why?
|
| Treatment Outcome | 13 | 2020 | 3618 | 0.390 |
Why?
|
| Ginkgo biloba | 4 | 2017 | 20 | 0.390 |
Why?
|
| Plant Extracts | 4 | 2019 | 64 | 0.390 |
Why?
|
| Personality | 2 | 2019 | 15 | 0.390 |
Why?
|
| Telephone | 2 | 2012 | 67 | 0.380 |
Why?
|
| Overweight | 5 | 2018 | 288 | 0.380 |
Why?
|
| Ethnic Groups | 6 | 2018 | 483 | 0.380 |
Why?
|
| Cross-Sectional Studies | 12 | 2019 | 1607 | 0.380 |
Why?
|
| Prospective Studies | 15 | 2020 | 2461 | 0.380 |
Why?
|
| Proxy | 2 | 2015 | 9 | 0.370 |
Why?
|
| Neoplasms | 1 | 2019 | 791 | 0.360 |
Why?
|
| Alcohol Drinking | 3 | 2019 | 260 | 0.360 |
Why?
|
| Residence Characteristics | 4 | 2019 | 188 | 0.360 |
Why?
|
| Double-Blind Method | 13 | 2019 | 597 | 0.360 |
Why?
|
| Religion and Medicine | 1 | 2011 | 19 | 0.330 |
Why?
|
| Radiation Injuries | 3 | 2013 | 86 | 0.330 |
Why?
|
| Depression | 6 | 2019 | 458 | 0.320 |
Why?
|
| Memory Disorders | 1 | 2010 | 58 | 0.310 |
Why?
|
| Progesterone Congeners | 3 | 2006 | 22 | 0.310 |
Why?
|
| Health Surveys | 4 | 2019 | 202 | 0.310 |
Why?
|
| Pilot Projects | 6 | 2017 | 583 | 0.310 |
Why?
|
| Skin Diseases | 3 | 2008 | 148 | 0.300 |
Why?
|
| Attitude to Health | 1 | 2011 | 161 | 0.300 |
Why?
|
| Environment Design | 2 | 2020 | 15 | 0.300 |
Why?
|
| Exercise | 5 | 2020 | 700 | 0.290 |
Why?
|
| Cohort Studies | 11 | 2020 | 1910 | 0.270 |
Why?
|
| Psoriasis | 4 | 2011 | 362 | 0.270 |
Why?
|
| Apolipoproteins E | 4 | 2019 | 90 | 0.270 |
Why?
|
| Obesity | 5 | 2018 | 1244 | 0.250 |
Why?
|
| Platelet Aggregation | 4 | 2010 | 31 | 0.250 |
Why?
|
| Sickness Impact Profile | 2 | 2006 | 41 | 0.250 |
Why?
|
| Apolipoprotein E4 | 4 | 2019 | 59 | 0.240 |
Why?
|
| Social Adjustment | 1 | 2006 | 11 | 0.240 |
Why?
|
| Weight Loss | 3 | 2020 | 493 | 0.240 |
Why?
|
| Health Status | 5 | 2019 | 411 | 0.240 |
Why?
|
| Asian Americans | 3 | 2018 | 96 | 0.230 |
Why?
|
| Pyridines | 3 | 2010 | 87 | 0.230 |
Why?
|
| Glutamic Acid | 3 | 2010 | 50 | 0.220 |
Why?
|
| Glioma | 1 | 2006 | 138 | 0.220 |
Why?
|
| Time Factors | 7 | 2020 | 2352 | 0.210 |
Why?
|
| Stroke | 3 | 2019 | 700 | 0.210 |
Why?
|
| Disability Evaluation | 5 | 2020 | 262 | 0.210 |
Why?
|
| Tamoxifen | 3 | 2013 | 66 | 0.200 |
Why?
|
| European Continental Ancestry Group | 3 | 2018 | 1176 | 0.200 |
Why?
|
| Logistic Models | 8 | 2019 | 808 | 0.190 |
Why?
|
| Learning | 2 | 2015 | 88 | 0.190 |
Why?
|
| Risk Assessment | 4 | 2018 | 1506 | 0.190 |
Why?
|
| Hispanic Americans | 6 | 2018 | 948 | 0.190 |
Why?
|
| Exercise Therapy | 2 | 2015 | 283 | 0.190 |
Why?
|
| Ultraviolet Rays | 3 | 2008 | 52 | 0.180 |
Why?
|
| Brain Ischemia | 2 | 2020 | 160 | 0.180 |
Why?
|
| Odds Ratio | 5 | 2019 | 480 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 849 | 0.170 |
Why?
|
| Dietary Supplements | 2 | 2019 | 197 | 0.170 |
Why?
|
| Plant Preparations | 2 | 2012 | 29 | 0.170 |
Why?
|
| Phytotherapy | 2 | 2012 | 41 | 0.170 |
Why?
|
| Young Adult | 3 | 2018 | 2825 | 0.170 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2017 | 96 | 0.170 |
Why?
|
| Self-Help Devices | 1 | 2020 | 8 | 0.170 |
Why?
|
| Accidents, Home | 1 | 2020 | 10 | 0.170 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 30 | 0.170 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 72 | 0.160 |
Why?
|
| Vision Disorders | 1 | 2020 | 25 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 819 | 0.160 |
Why?
|
| Cholesterol | 2 | 2019 | 273 | 0.160 |
Why?
|
| Housing | 1 | 2020 | 65 | 0.160 |
Why?
|
| Sleep | 1 | 2020 | 90 | 0.160 |
Why?
|
| Hearing Loss | 1 | 2020 | 26 | 0.160 |
Why?
|
| Particulate Matter | 1 | 2020 | 32 | 0.160 |
Why?
|
| Visual Acuity | 1 | 2020 | 76 | 0.150 |
Why?
|
| Magnesium | 1 | 2019 | 30 | 0.150 |
Why?
|
| Cacao | 1 | 2019 | 4 | 0.150 |
Why?
|
| Polysomnography | 2 | 2017 | 41 | 0.150 |
Why?
|
| Piperazines | 2 | 2010 | 64 | 0.150 |
Why?
|
| Radiotherapy Dosage | 1 | 2019 | 110 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2020 | 133 | 0.150 |
Why?
|
| Optic Nerve | 1 | 2019 | 17 | 0.150 |
Why?
|
| Fibrinolytic Agents | 2 | 2010 | 71 | 0.150 |
Why?
|
| Sweetening Agents | 1 | 2019 | 8 | 0.150 |
Why?
|
| Continental Population Groups | 2 | 2018 | 245 | 0.150 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 21 | 0.150 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2010 | 94 | 0.150 |
Why?
|
| Environmental Exposure | 1 | 2020 | 91 | 0.150 |
Why?
|
| Beverages | 1 | 2019 | 19 | 0.150 |
Why?
|
| Optic Nerve Diseases | 1 | 2019 | 19 | 0.150 |
Why?
|
| North Carolina | 5 | 2012 | 1612 | 0.150 |
Why?
|
| African Americans | 3 | 2018 | 1435 | 0.150 |
Why?
|
| Psychometrics | 2 | 2012 | 143 | 0.150 |
Why?
|
| Vitamins | 1 | 2019 | 75 | 0.140 |
Why?
|
| Risk | 6 | 2020 | 325 | 0.140 |
Why?
|
| Problem Solving | 1 | 2018 | 29 | 0.140 |
Why?
|
| Patient Education as Topic | 2 | 2017 | 261 | 0.140 |
Why?
|
| Mortality | 1 | 2019 | 127 | 0.140 |
Why?
|
| Heart Rate | 1 | 2020 | 372 | 0.140 |
Why?
|
| Psychological Tests | 4 | 2015 | 34 | 0.140 |
Why?
|
| Computers, Handheld | 1 | 2017 | 15 | 0.140 |
Why?
|
| Hepatitis B virus | 1 | 2017 | 6 | 0.140 |
Why?
|
| Motor Activity | 2 | 2011 | 356 | 0.140 |
Why?
|
| Ribonuclease H | 1 | 2017 | 7 | 0.140 |
Why?
|
| Hostility | 1 | 2017 | 4 | 0.140 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 18 | 0.130 |
Why?
|
| Virus Replication | 1 | 2017 | 43 | 0.130 |
Why?
|
| Depressive Disorder | 1 | 2018 | 76 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2016 | 323 | 0.130 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2017 | 28 | 0.130 |
Why?
|
| Death Certificates | 1 | 2017 | 5 | 0.130 |
Why?
|
| Methylphenidate | 2 | 2007 | 39 | 0.130 |
Why?
|
| Agricultural Workers' Diseases | 2 | 2008 | 84 | 0.130 |
Why?
|
| Diet Surveys | 1 | 2017 | 56 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 200 | 0.130 |
Why?
|
| Sex Characteristics | 1 | 2018 | 182 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 22 | 0.130 |
Why?
|
| Behavior, Addictive | 2 | 2008 | 40 | 0.130 |
Why?
|
| Antiviral Agents | 1 | 2017 | 110 | 0.130 |
Why?
|
| Prevalence | 6 | 2019 | 1034 | 0.130 |
Why?
|
| Algorithms | 4 | 2019 | 560 | 0.130 |
Why?
|
| Prognosis | 6 | 2020 | 1603 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 302 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2018 | 378 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 2 | 2007 | 85 | 0.120 |
Why?
|
| Adolescent | 8 | 2010 | 3799 | 0.120 |
Why?
|
| Loneliness | 1 | 2016 | 9 | 0.120 |
Why?
|
| Walking | 3 | 2019 | 217 | 0.120 |
Why?
|
| Decision Making | 1 | 2018 | 203 | 0.120 |
Why?
|
| Dermatitis, Atopic | 2 | 2011 | 103 | 0.120 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 78 | 0.120 |
Why?
|
| Severity of Illness Index | 6 | 2012 | 922 | 0.120 |
Why?
|
| Facial Dermatoses | 2 | 2006 | 18 | 0.120 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 60 | 0.110 |
Why?
|
| Automobile Driving | 1 | 2015 | 26 | 0.110 |
Why?
|
| Nursing Homes | 1 | 2015 | 33 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2015 | 23 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2019 | 3812 | 0.110 |
Why?
|
| Analysis of Variance | 4 | 2012 | 508 | 0.110 |
Why?
|
| Organ Size | 3 | 2020 | 236 | 0.110 |
Why?
|
| Meningioma | 1 | 2015 | 59 | 0.110 |
Why?
|
| Chi-Square Distribution | 4 | 2011 | 304 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 214 | 0.110 |
Why?
|
| Age Factors | 5 | 2020 | 1261 | 0.110 |
Why?
|
| Choice Behavior | 2 | 2006 | 88 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 439 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 231 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2015 | 161 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 589 | 0.100 |
Why?
|
| Women's Health Services | 1 | 2013 | 12 | 0.100 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 2 | 2003 | 4 | 0.100 |
Why?
|
| Symporters | 2 | 2003 | 13 | 0.100 |
Why?
|
| Artificial Intelligence | 1 | 2013 | 66 | 0.100 |
Why?
|
| Health Promotion | 1 | 2015 | 264 | 0.100 |
Why?
|
| Atrophy | 1 | 2013 | 51 | 0.100 |
Why?
|
| Mobility Limitation | 1 | 2014 | 222 | 0.100 |
Why?
|
| Mood Disorders | 1 | 2012 | 22 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2013 | 163 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 464 | 0.090 |
Why?
|
| Pruritus | 1 | 2011 | 47 | 0.090 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 446 | 0.090 |
Why?
|
| Religion and Psychology | 1 | 2011 | 7 | 0.090 |
Why?
|
| Research Design | 3 | 2014 | 337 | 0.080 |
Why?
|
| Physical Exertion | 1 | 2011 | 15 | 0.080 |
Why?
|
| Remote Consultation | 1 | 2011 | 14 | 0.080 |
Why?
|
| Nootropic Agents | 1 | 2011 | 14 | 0.080 |
Why?
|
| Disease Progression | 1 | 2013 | 633 | 0.080 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 703 | 0.080 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2010 | 38 | 0.080 |
Why?
|
| Structure-Activity Relationship | 4 | 2010 | 88 | 0.080 |
Why?
|
| Cholesterol, LDL | 2 | 2018 | 185 | 0.080 |
Why?
|
| Hysterectomy | 1 | 2009 | 55 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2019 | 953 | 0.070 |
Why?
|
| Beauty Culture | 2 | 2006 | 7 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 168 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2009 | 80 | 0.070 |
Why?
|
| Heterozygote | 2 | 2019 | 66 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2010 | 127 | 0.070 |
Why?
|
| Cosmetics | 2 | 2006 | 11 | 0.070 |
Why?
|
| Mass Screening | 1 | 2011 | 268 | 0.070 |
Why?
|
| Cosmetic Techniques | 1 | 2008 | 11 | 0.070 |
Why?
|
| Focus Groups | 2 | 2006 | 125 | 0.070 |
Why?
|
| Genotype | 2 | 2019 | 743 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 140 | 0.060 |
Why?
|
| Interviews as Topic | 3 | 2017 | 272 | 0.060 |
Why?
|
| Cyclic N-Oxides | 2 | 2003 | 8 | 0.060 |
Why?
|
| Bile Acids and Salts | 2 | 2003 | 10 | 0.060 |
Why?
|
| Gait | 1 | 2007 | 134 | 0.060 |
Why?
|
| Tropanes | 2 | 2003 | 14 | 0.060 |
Why?
|
| Anger | 1 | 2006 | 4 | 0.060 |
Why?
|
| Naltrexone | 1 | 2006 | 23 | 0.060 |
Why?
|
| Women | 1 | 2006 | 13 | 0.060 |
Why?
|
| Electroconvulsive Therapy | 1 | 2006 | 30 | 0.060 |
Why?
|
| Narcotic Antagonists | 1 | 2006 | 47 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2006 | 41 | 0.060 |
Why?
|
| Receptors, Purinergic P2 | 3 | 2010 | 11 | 0.060 |
Why?
|
| Animals | 7 | 2017 | 8544 | 0.060 |
Why?
|
| Body Composition | 1 | 2007 | 415 | 0.060 |
Why?
|
| Occupational Exposure | 1 | 2008 | 237 | 0.060 |
Why?
|
| Pigmentation Disorders | 1 | 2005 | 8 | 0.060 |
Why?
|
| Rats | 4 | 2010 | 1946 | 0.060 |
Why?
|
| Administration, Oral | 3 | 2010 | 212 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2006 | 239 | 0.050 |
Why?
|
| Skin | 1 | 2006 | 222 | 0.050 |
Why?
|
| Medroxyprogesterone | 1 | 2004 | 15 | 0.050 |
Why?
|
| Cricetinae | 3 | 2010 | 52 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2006 | 186 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 46 | 0.050 |
Why?
|
| Foot Dermatoses | 1 | 2003 | 9 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 120 | 0.050 |
Why?
|
| Hand Dermatoses | 1 | 2003 | 10 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 124 | 0.050 |
Why?
|
| Ileum | 1 | 2003 | 16 | 0.050 |
Why?
|
| Dermatology | 1 | 2005 | 164 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 135 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 150 | 0.050 |
Why?
|
| Parent-Child Relations | 1 | 2003 | 48 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2002 | 49 | 0.050 |
Why?
|
| Attitude | 1 | 2002 | 43 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 270 | 0.040 |
Why?
|
| Child | 2 | 2006 | 2613 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2002 | 149 | 0.040 |
Why?
|
| Exercise Test | 2 | 2016 | 247 | 0.040 |
Why?
|
| Osteoarthritis | 1 | 2002 | 80 | 0.040 |
Why?
|
| Caregivers | 1 | 2003 | 116 | 0.040 |
Why?
|
| Sleep, REM | 1 | 2020 | 6 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2017 | 484 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2002 | 177 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2020 | 76 | 0.040 |
Why?
|
| Cricetulus | 2 | 2010 | 21 | 0.040 |
Why?
|
| CHO Cells | 2 | 2010 | 29 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2013 | 310 | 0.040 |
Why?
|
| Apolipoprotein E2 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 129 | 0.040 |
Why?
|
| Population Density | 1 | 2019 | 9 | 0.040 |
Why?
|
| Biological Availability | 2 | 2010 | 23 | 0.040 |
Why?
|
| Creatinine | 1 | 2020 | 206 | 0.040 |
Why?
|
| Drinking Behavior | 1 | 2019 | 11 | 0.040 |
Why?
|
| Albuminuria | 1 | 2020 | 181 | 0.040 |
Why?
|
| Optic Disk | 1 | 2019 | 11 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 315 | 0.040 |
Why?
|
| Adiposity | 1 | 2020 | 204 | 0.040 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2019 | 14 | 0.040 |
Why?
|
| Dermatologic Agents | 1 | 2002 | 235 | 0.040 |
Why?
|
| Intraocular Pressure | 1 | 2019 | 41 | 0.040 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2019 | 10 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 62 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2019 | 38 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 41 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2019 | 40 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2018 | 18 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 343 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 86 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 67 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 225 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 924 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 176 | 0.030 |
Why?
|
| China | 1 | 2018 | 58 | 0.030 |
Why?
|
| Sleep Stages | 1 | 2017 | 6 | 0.030 |
Why?
|
| Hepatitis B | 1 | 2017 | 17 | 0.030 |
Why?
|
| Single-Blind Method | 2 | 2011 | 214 | 0.030 |
Why?
|
| DNA Replication | 1 | 2017 | 35 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 194 | 0.030 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 15 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2017 | 24 | 0.030 |
Why?
|
| Urban Population | 1 | 2018 | 97 | 0.030 |
Why?
|
| Caloric Restriction | 1 | 2018 | 121 | 0.030 |
Why?
|
| Triglycerides | 1 | 2018 | 249 | 0.030 |
Why?
|
| Placebos | 2 | 2009 | 69 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 270 | 0.030 |
Why?
|
| Patient Dropouts | 2 | 2007 | 28 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2009 | 923 | 0.030 |
Why?
|
| Data Collection | 2 | 2010 | 191 | 0.030 |
Why?
|
| Language | 2 | 2007 | 45 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2016 | 69 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 925 | 0.030 |
Why?
|
| Mice | 2 | 2017 | 2691 | 0.030 |
Why?
|
| Oximetry | 1 | 2016 | 33 | 0.030 |
Why?
|
| Muscle Stretching Exercises | 1 | 2015 | 5 | 0.030 |
Why?
|
| Social Support | 1 | 2017 | 195 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 214 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 248 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 1078 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2015 | 68 | 0.030 |
Why?
|
| Self Care | 1 | 2016 | 144 | 0.030 |
Why?
|
| Culture | 1 | 2015 | 41 | 0.030 |
Why?
|
| Transients and Migrants | 2 | 2008 | 304 | 0.030 |
Why?
|
| Resistance Training | 1 | 2015 | 84 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2017 | 488 | 0.030 |
Why?
|
| Health Education | 1 | 2015 | 170 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 26 | 0.030 |
Why?
|
| Radiography | 1 | 2013 | 397 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 500 | 0.020 |
Why?
|
| Pleasure | 1 | 2011 | 1 | 0.020 |
Why?
|
| Shame | 1 | 2011 | 3 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 2011 | 30 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 1209 | 0.020 |
Why?
|
| Perception | 1 | 2011 | 107 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2010 | 4 | 0.020 |
Why?
|
| Multilevel Analysis | 1 | 2010 | 4 | 0.020 |
Why?
|
| Censuses | 1 | 2010 | 10 | 0.020 |
Why?
|
| Glutamates | 1 | 2010 | 11 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 107 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 28 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2010 | 60 | 0.020 |
Why?
|
| Social Environment | 1 | 2010 | 82 | 0.020 |
Why?
|
| Internet | 1 | 2011 | 207 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 96 | 0.020 |
Why?
|
| Space Perception | 1 | 2009 | 30 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 114 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 130 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 306 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2009 | 10 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 281 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2008 | 23 | 0.020 |
Why?
|
| Counseling | 1 | 2008 | 99 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2007 | 28 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 627 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2007 | 35 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 79 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 128 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 112 | 0.010 |
Why?
|
| Self Concept | 1 | 2006 | 47 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2006 | 76 | 0.010 |
Why?
|
| Mexico | 1 | 2005 | 72 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 245 | 0.010 |
Why?
|
| Skin Pigmentation | 1 | 2004 | 27 | 0.010 |
Why?
|
| Biological Transport | 1 | 2003 | 76 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2003 | 68 | 0.010 |
Why?
|
| Heptanoic Acids | 1 | 2003 | 35 | 0.010 |
Why?
|
| Home Nursing | 1 | 2003 | 9 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2003 | 24 | 0.010 |
Why?
|
| Skin Absorption | 1 | 2002 | 9 | 0.010 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2002 | 3 | 0.010 |
Why?
|
| Swine, Miniature | 1 | 2002 | 6 | 0.010 |
Why?
|
| Pyrroles | 1 | 2003 | 62 | 0.010 |
Why?
|
| Solutions | 1 | 2002 | 41 | 0.010 |
Why?
|
| Lipoproteins, VLDL | 1 | 2002 | 27 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 185 | 0.010 |
Why?
|
| Personality Assessment | 1 | 2002 | 9 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2002 | 99 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2002 | 146 | 0.010 |
Why?
|
| Receptors, LDL | 1 | 2002 | 67 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 259 | 0.010 |
Why?
|
| Swine | 1 | 2002 | 230 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2002 | 113 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 282 | 0.010 |
Why?
|
| Physical Fitness | 1 | 2002 | 135 | 0.010 |
Why?
|
| Lipids | 1 | 2002 | 267 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2002 | 145 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2003 | 887 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2003 | 233 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 545 | 0.010 |
Why?
|
| Liver | 1 | 2002 | 510 | 0.010 |
Why?
|
| Infant | 1 | 2003 | 1122 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 1354 | 0.010 |
Why?
|